ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $342,000 | +26.2% | 10,200 | 0.0% | 0.23% | +145.7% |
| Q3 2016 | $271,000 | +20.4% | 10,200 | 0.0% | 0.09% | +2.2% |
| Q2 2016 | $225,000 | -25.0% | 10,200 | 0.0% | 0.09% | -28.0% |
| Q1 2016 | $300,000 | -11.0% | 10,200 | 0.0% | 0.12% | +31.6% |
| Q4 2015 | $337,000 | -8.7% | 10,200 | 0.0% | 0.10% | +33.8% |
| Q3 2015 | $369,000 | -94.4% | 10,200 | -93.0% | 0.07% | -88.5% |
| Q2 2015 | $6,582,000 | +41.6% | 146,300 | -3.6% | 0.62% | +41.2% |
| Q1 2015 | $4,648,000 | -42.3% | 151,800 | -4.2% | 0.44% | -43.1% |
| Q4 2014 | $8,055,000 | +27.9% | 158,400 | -0.4% | 0.77% | +18.8% |
| Q3 2014 | $6,296,000 | -33.3% | 159,100 | -27.4% | 0.65% | -19.9% |
| Q2 2014 | $9,441,000 | +9.0% | 219,200 | +1.2% | 0.81% | +14.7% |
| Q1 2014 | $8,662,000 | +17.4% | 216,600 | -19.9% | 0.71% | +16.9% |
| Q4 2013 | $7,377,000 | +26.3% | 270,400 | +6.1% | 0.60% | +11.0% |
| Q3 2013 | $5,842,000 | +25.5% | 254,900 | -3.0% | 0.54% | +14.7% |
| Q2 2013 | $4,654,000 | – | 262,800 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |